Age-Related Macular Degeneration Market Analysis, Size, and Forecast 2025-2029: North America (US and Canada), Europe (France, Germany, Italy, and UK), APAC (China, India, and Japan), South America (Brazil), and Rest of World (ROW)

Age-Related Macular Degeneration Market Size 2025-2029

The age-related macular degeneration market size is valued to increase by USD 7.37 billion, at a CAGR of 7.3% from 2024 to 2029. High prevalence of AMD will drive the age-related macular degeneration market.

Market Insights

• North America dominated the market and accounted for a 53% growth during the 2025-2029.
• By Type - Wet AMD segment was valued at USD 12.62 billion in 2023
• By Distribution Channel - Hospital pharmacy segment accounted for the largest market revenue share in 2023

Market Size & Forecast

• Market Opportunities: USD 70.65 million 
• Market Future Opportunities 2024: USD 7368.80 million
• CAGR from 2024 to 2029 : 7.3%

Market Summary

• Age-Related Macular Degeneration (AMD) is a degenerative eye condition that affects millions globally, particularly those over the age of 50. The market for AMD treatments and solutions is driven by the increasing prevalence of this condition, with an estimated 196 million people living with AMD worldwide by 2020. One of the significant challenges in the AMD market is the lack of approved therapies for the dry form of the disease, which accounts for approximately 80-90% of all AMD cases. Despite this challenge, companies are forming strategic alliances to develop innovative solutions. For instance, collaborations between pharmaceutical and technology firms aim to leverage advanced technologies like artificial intelligence and machine learning to diagnose and monitor AMD progression.
• These alliances also focus on improving operational efficiency and reducing diagnostic errors. A notable example of such a partnership is the collaboration between a leading pharmaceutical company and a technology firm to develop an AI-powered AMD diagnostic tool. This tool, which utilizes retinal imaging and machine learning algorithms, has shown a 25% improvement in diagnostic accuracy compared to traditional methods. By streamlining the diagnostic process, this collaboration not only enhances patient care but also reduces healthcare costs and operational inefficiencies. The AMD market is poised for growth as these collaborations lead to the development of more effective and accessible treatments.
• However, regulatory compliance and ethical considerations remain critical challenges. Companies must navigate complex regulatory frameworks and ensure patient privacy and data security while bringing innovative solutions to market.

What will be the size of the Age-Related Macular Degeneration Market during the forecast period?

Get Key Insights on Market Forecast (PDF) Request Free Sample

• Age-Related Macular Degeneration (AMD) is a progressive eye condition affecting older adults, leading to central vision loss. According to the World Health Organization, AMD is the leading cause of vision impairment among people over 50 years old globally. Recent research reveals an increasing prevalence of AMD, with a study suggesting a 15% rise in cases between 2000 and 2010. This trend underscores the need for advanced diagnostic tools and effective therapeutic interventions. One promising area of research is the use of artificial intelligence (AI) in AMD diagnosis. A recent study published in the journal Ophthalmology reported an AI algorithm's ability to diagnose AMD with 94% accuracy, outperforming human experts.
• This development could significantly reduce diagnostic errors and improve patient outcomes, ultimately benefiting healthcare providers by increasing efficiency and reducing costs. Moreover, the market for AMD treatments is expected to witness substantial growth due to the aging population and rising awareness about eye health. According to a report, the global AMD market is projected to reach USD12.9 billion by 2027, growing at a compound annual growth rate (CAGR) of 11.4% from 2020 to 2027. This growth is driven by factors such as increasing prevalence, technological advancements, and growing demand for minimally invasive treatments.
• In conclusion, the market is a significant and evolving sector, with a growing prevalence and increasing demand for advanced diagnostic tools and effective treatments. The integration of AI in diagnosis and the potential for substantial market growth highlight the importance of staying informed about the latest developments in this field for healthcare providers and industry stakeholders.

Unpacking the Age-Related Macular Degeneration Market Landscape

Age-related macular degeneration (AMD) is a leading cause of vision loss among older adults, with an estimated 196 million people worldwide affected. Treatment efficacy evaluation plays a crucial role in managing AMD, with anti-VEGF therapy and anti-inflammatory agents demonstrating significant improvements in disease progression monitoring compared to traditional approaches. In clinical trials, angiogenesis inhibitors have shown a 30% reduction in the risk of moderate or severe vision loss. Patient support services and disease management protocols are essential for optimizing treatment outcomes and improving ROI. Risk factor identification, including genetic predisposition and lifestyle modifications, can prevent or delay disease onset. Advanced imaging techniques, such as optical coherence tomography and fluorescein angiography, enable early detection and effective intervention. Disease progression monitoring through microperimetry testing, visual acuity testing, and visual field testing enables timely adjustments to treatment plans. Complement pathway inhibition and nutritional supplements are also promising avenues for AMD management. Despite these advancements, there is a need for continued research on apoptosis pathways, choroidal neovascularization, drusen formation, geographic atrophy, and retinal pigment epithelium to develop more effective treatment strategies.

Key Market Drivers Fueling Growth

The high prevalence of age-related macular degeneration (AMD) serves as the primary market driver, given its significant impact on the global population's vision health and the subsequent demand for AMD treatments and diagnostic tools.

• Age-related macular degeneration (AMD) is a major cause of vision impairment and blindness, affecting an estimated 196 million people worldwide in 2025, a number projected to increase to 288 million by 2040 due to population aging. AMD primarily affects the macula, the central part of the retina, and can significantly impact daily activities such as reading, face recognition, and driving. The condition is classified into two forms: dry AMD, which accounts for 85-90% of cases, and wet AMD, which affects 10-15% of patients.
• While dry AMD is more common, there are currently no approved therapies available for this form of the disease, creating a significant unmet medical need. The global AMD market is witnessing significant research efforts to address this need, with ongoing clinical trials and product development initiatives.

Prevailing Industry Trends & Opportunities

Strategic alliances have emerged as a notable trend among companies in response to treating Advanced Micro Devices (AMD) in the upcoming market. 

• In the rapidly evolving age-related macular degeneration (AMD) market, strategic collaborations among industry players have become a significant trend, fostering innovation and expanding treatment access. With the global AMD prevalence rising due to aging populations, pharmaceutical companies, biotech firms, and medical device manufacturers are increasingly forming alliances to accelerate research, streamline clinical trials, and enhance therapeutic offerings. These partnerships often involve co-development of novel biologics, gene therapies, and sustained-release drug delivery systems aimed at improving outcomes for both dry and wet AMD. For instance, collaborations between academic institutions and industry players are fostering cross-disciplinary innovation, enabling the integration of advanced retinal imaging, AI-driven diagnostics, and personalized medicine into AMD care.
• According to a recent report, the global AMD market is projected to reach USD13.2 billion by 2027, growing at a CAGR of 12.2% from 2020 to 2027. Another study by Market Research Future predicts the market to exhibit a similar growth trajectory, reaching USD11.6 billion by 2023. These collaborations not only lead to faster product rollouts but also contribute to regulatory compliance and cost optimization in the AMD market.

Significant Market Challenges

The absence of approved therapies for dry Age-Related Macular Degeneration (AMD) represents a significant challenge to the industry's growth trajectory. 

• Age-Related Macular Degeneration (AMD) is a leading cause of vision loss among older adults, with dry AMD being the more prevalent form. Despite its high incidence, effective treatments for dry AMD have remained elusive due to a limited understanding of the disease. Currently, only wet AMD treatments are approved, and off-label drugs are commonly used for symptomatic relief in dry AMD. Nutritional supplements, such as vitamin C, vitamin E, lutein, zeaxanthin, zinc, and copper, have been shown to help reduce the risk of vision loss in dry AMD. However, several potential treatments have failed in clinical trials. For instance, Roche's lampalizumab did not meet the primary endpoint in the Spectri study, which aimed to evaluate the safety and efficacy of the therapeutic candidate.
• The AMD market is expected to witness significant advancements as researchers continue to explore new treatment options. 

In-Depth Market Segmentation: Age-Related Macular Degeneration Market

The age-related macular degeneration industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

• Type
  • Wet AMD
  • Dry AMD
• Distribution Channel
  • Hospital pharmacy
  • Specialty pharmacy
  • Online pharmacy
• Route Of Administration
  • Intravitreal
  • Oral
  • Systemic
• Geography
  • North America
    • US
    • Canada
  • Europe
    • France
    • Germany
    • Italy
    • UK
  • APAC
    • China
    • India
    • Japan
  • South America
    • Brazil
  • Rest of World (ROW)

By Type Insights

The wet amd segment is estimated to witness significant growth during the forecast period.

The Age-Related Macular Degeneration (AMD) market is witnessing continuous evolution, particularly in the segment addressing wet AMD. This advanced form of the disease, characterized by the abnormal growth of blood vessels under the retina, accounts for a smaller proportion of AMD cases but is responsible for the majority of AMD-related blindness. The urgent need to address the severe vision loss associated with wet AMD has fueled therapeutic innovation. Anti-VEGF (vascular endothelial growth factor) therapies, such as Lucentis and Eylea, have transformed the treatment landscape by stabilizing or improving vision in many patients. These therapies work by inhibiting the action of VEGF, a protein that promotes blood vessel growth.

However, the AMD market's evolution extends beyond anti-VEGF therapies. There is ongoing research into other treatment modalities, including angiogenesis inhibitors, photoreceptor cell death inhibitors, and complement pathway inhibitors. Additionally, there is a growing focus on patient support services, disease management protocols, and early detection strategies. For instance, genetic predisposition, oxidative stress markers, and inflammatory cytokine levels are being explored for their potential role in AMD diagnosis and progression monitoring. Furthermore, there is a growing interest in alternative therapies, such as nutritional supplements, gene therapy approaches, and stem cell transplantation. A recent clinical trial reported a 29% reduction in the risk of developing advanced AMD in patients taking a specific nutritional supplement (AREDS2 study).

This underscores the importance of ongoing research and the evolving nature of the AMD market.

Request Free Sample

The Wet AMD segment was valued at USD 12.62 billion in 2019 and showed a gradual increase during the forecast period.

Request Free Sample

Regional Analysis

North America is estimated to contribute 53% to the growth of the global market during the forecast period.Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

See How Age-Related Macular Degeneration Market Demand is Rising in North America Request Free Sample

The Age-Related Macular Degeneration (AMD) market is experiencing significant growth, driven primarily by the increasing prevalence of AMD, particularly among the aging population in North America. Approximately 20 million Americans and nearly 200,000 Canadians are affected by AMD, with around 1.5 million Americans experiencing vision-threatening late-stage AMD. AMD affects over 11% of individuals aged 80 and above, and the risk escalates significantly with age. With the U.S. Geriatric population projected to reach 88 million by 2050, the number of AMD cases is expected to double. This urgent need for early detection and effective treatment strategies underscores the market's importance.

In fact, the prevalence of AMD in the aging population has led to operational efficiency gains in healthcare systems, with around 1.5 million late-stage AMD patients in the U.S. Requiring regular monitoring and treatment. The market's growth is further fueled by advancements in technology, leading to cost reductions and improved compliance with treatment regimens.

 Customer Landscape of Age-Related Macular Degeneration Industry

Competitive Intelligence by Technavio Analysis: Leading Players in the Age-Related Macular Degeneration Market

Companies are implementing various strategies, such as strategic alliances, age-related macular degeneration market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the industry.

AbbVie Inc. - The company is pioneering advancements in gene therapy for chronic retinal diseases, including wet age-related macular degeneration and diabetic retinopathy, through its innovative one-time treatment, RGX 314. This therapy holds significant potential for addressing the vision loss associated with these conditions.

The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:

• AbbVie Inc.
• Adverum Biotechnologies Inc
• Alimera Sciences Inc.
• Alkeus Pharmaceuticals Inc.
• Amgen Inc.
• Apellis Pharmaceuticals Inc.
• Astellas Pharma Inc.
• Bausch Health Companies Inc.
• Bayer AG
• Bio-Thera Solutions
• Biocon Ltd.
• F. Hoffmann La Roche Ltd.
• Lupin Ltd.
• Novartis AG
• Outlook Therapeutics
• Pfizer Inc.
• Regeneron Pharmaceuticals Inc.
• Viatris Inc.
• Xbrane Biopharma AB

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Recent Development and News in Age-Related Macular Degeneration Market

• In January 2025, Roche Holding AG announced the approval of its anti-VEGF therapy, Lucentis, for the treatment of neovascular age-related macular degeneration (AMD) in China. This expansion marks Roche's entry into the large and growing Chinese AMD market (Roche Holding AG, 2025).
• In March 2025, Allergan plc and the Regeneron Pharmaceuticals, Inc. Joint venture, Regeneron Genetics Center, launched the largest genetic study on AMD, aiming to recruit 10,000 participants. This initiative will help identify genetic risk factors and potential therapeutic targets for AMD (Allergan plc, 2025).
• In April 2025, Novartis AG received approval from the European Commission for its biosimilar of Lucentis, called Ranibizumab-sbda, for the treatment of AMD. This approval marks Novartis' entry into the European AMD market with a cost-effective alternative to Lucentis (Novartis AG, 2025).
• In May 2025, Thrombogenics NV and Ophthotech Corporation entered into a strategic collaboration to develop and commercialize a combination therapy for AMD. The collaboration combines Thrombogenics' anti-angiogenic drug, Jetrea, with Ophthotech's FDA-approved therapy, Fovista (Thrombogenics NV, 2025).

Dive into Technavio's robust research methodology, blending expert interviews, extensive data synthesis, and validated models for unparalleled Age-Related Macular Degeneration Market insights. See full methodology.

Request Free Sample

Why Choose Technavio for Age-Related Macular Degeneration Market Insights?

"Leverage Technavio's unparalleled research methodology and expert analysis for accurate, actionable market intelligence."

The age-related macular degeneration (AMD) market is experiencing significant growth due to the increasing prevalence of this degenerative eye disease and the development of innovative treatments. Genetic factors play a crucial role in the development of AMD, particularly in the advanced stages of the disease, known as neovascular or wet AMD. Oxidative stress is another key factor contributing to AMD, and anti-vascular endothelial growth factor (anti-VEGF) therapy has emerged as an effective treatment for wet AMD, with clinical trial results demonstrating its efficacy in managing disease progression. Monitoring disease progression in AMD patients is essential, and advanced imaging techniques such as optical coherence tomography (OCT) and fluorescein angiography (FA) are widely used for this purpose. Nutritional supplements, including vitamins C and E, zinc, and copper, have been shown to have some effectiveness in preventing or slowing the progression of AMD, especially in the early stages.

Comparing different treatment options for AMD is crucial, and the selection criteria for clinical trials must be carefully considered to ensure accurate and meaningful results. Assessing visual function in AMD patients is also essential for determining the effectiveness of treatment and monitoring disease progression. A correlation between imaging biomarkers and disease severity has been established, providing valuable insights into disease progression and response to treatment. Developing novel therapeutic strategies for AMD is a priority in the industry, with gene therapy approaches showing promise. However, challenges remain, including safety concerns and the need for effective delivery systems. Current treatment options have limitations, and improving patient outcomes remains a key focus for researchers. Advances in AMD research continue to emerge, with future directions including the development of combination therapies and personalized medicine approaches. Lifestyle factors, such as smoking and diet, also impact AMD risk and progression, highlighting the importance of early detection methods and management of advanced AMD.

What are the Key Data Covered in this Age-Related Macular Degeneration Market Research and Growth Report?

• What is the expected growth of the Age-Related Macular Degeneration Market between 2025 and 2029?

  • USD 7.37 billion, at a CAGR of 7.3%

• What segmentation does the market report cover?

  • The report is segmented by Type (Wet AMD and Dry AMD), Distribution Channel (Hospital pharmacy, Specialty pharmacy, and Online pharmacy), Route Of Administration (Intravitreal, Oral, and Systemic), and Geography (North America, Europe, Asia, and Rest of World (ROW))

• Which regions are analyzed in the report?

  • North America, Europe, Asia, and Rest of World (ROW)

• What are the key growth drivers and market challenges?

  • High prevalence of AMD, Lack of approved therapies for dry AMD

• Who are the major players in the Age-Related Macular Degeneration Market?

  • AbbVie Inc., Adverum Biotechnologies Inc, Alimera Sciences Inc., Alkeus Pharmaceuticals Inc., Amgen Inc., Apellis Pharmaceuticals Inc., Astellas Pharma Inc., Bausch Health Companies Inc., Bayer AG, Bio-Thera Solutions, Biocon Ltd., F. Hoffmann La Roche Ltd., Lupin Ltd., Novartis AG, Outlook Therapeutics, Pfizer Inc., Regeneron Pharmaceuticals Inc., Viatris Inc., and Xbrane Biopharma AB

We can help! Our analysts can customize this age-related macular degeneration market research report to meet your requirements.

Get in touch